Stay tuned and follow the latest developments and news in Molecular Oncology.
The FRα test is performed for the administration of mirvetuximab soravtansine and is aimed at patients with platinum-resistant ovarian cancer who are FRα-positive and have received 1-3 lines of therapy.
On September 19, 2024, the EMA issued a positive opinion for the administration of mirvetuximab soravtansine to patients with FRα-positive, platinum-resistant ovarian cancer who have received 1-3 lines of therapy, based on the phase III MIRASOL study.
In the US mirvetuximab soravtansine is FDA approved since March 2024.
Our pathology lab in Thessaloniki now performs the test for this specific biomarker (FRa).
The determination of FOLR1 (FRα) is carried out immunohistochemically on biopsy material, surgical specimens, or tissue embedded in paraffin blocks.
The Ventana BenchMark Ultra automated platform is used.
In clinical practice, the sample is considered FOLR1 (FRα) positive if the neoplastic cells show moderate (2+) to intense (3+) complete or incomplete membrane staining in 75% or more of the sample.
The sample is acceptable if it contains at least one hundred viable cancer cells. A positive external control is used.
The experienced and specialized staff of Genekor is here to provide physicians with the most reliable and accurate results, in order to enhance their efforts to offer the best possible care to their patients.